

Level 8, 261 George Street  
Sydney NSW 2000  
Tel: (61-2) 9247 8212  
Fax: (61-2) 9247 3932  
E-mail: [pnightingale@biotron.com.au](mailto:pnightingale@biotron.com.au)  
Website: [www.biotron.com.au](http://www.biotron.com.au)

2 December 2004

The Manager - Companies  
Australian Stock Exchange Limited  
20 Bridge Street  
SYDNEY NSW 2000

(1 page by email)

Dear Madam,

### ISSUE OF KEY VIRION PATENT

The Directors are pleased to advise that the a major patent application covering the first generation of the Company's anti-HIV inhibitors has been accepted by the Australian patent office.

The patent covers the use of specific therapeutic compounds as antiviral agents, targeting the Vpu protein of HIV-1 virus. Patent applications by the Company for this invention are progressing in other key pharmaceutical markets, including the major US and European markets.


In addition to this patent, Biotron has several other international patent applications and issued patents covering a wider range of antiviral compounds, antiviral targets and antiviral assays. Biotron's portfolio of compounds and assays has laid the foundation for the Company's world-class antiviral technology, which may result in treatments for several viral diseases with huge market potential and unmet medical need.

The compounds covered in the granted Australian patent include compounds which inhibit replication of several viruses including HIV-1. The compounds target a different stage of the viral life cycle than existing drugs, preventing release of infectious virus from infected cells. The compounds specifically reduce viral levels in cells which act as reservoirs of infection in HIV-infected humans, indicating they may prevent occurrence of late-stage disease in AIDS patients. Biotron is in late preclinical development with an HIV-1 therapeutic in preparation for the commencement of clinical studies in humans.

With the continuing development of its range of specific therapeutic compounds, its unique antiviral platform technology and expanding patent portfolio, Biotron is well placed to capitalise on its position targeting the treatment of several economically significant viral diseases.

For further information, please contact Dr. Michelle Miller, CEO, on (61-2) 61258001.

Yours sincerely



Peter J. Nightingale  
Company Secretary

pjn2832